Results 51 to 60 of about 23,901 (228)

The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study

Scientific Reports
The present study aimed to compare clinical and radiological differences of ONFH patients who were treated with denosumab, and a control group. A total of 178 patients (272 hips) with symptomatic, nontraumatic ONFH were divided into a denosumab group (98
Jun-Ki Moon, Jinyong Park, Yisack Yoo, Jae Youn Yoon, Sunhyung Lee, Pil Whan Yoon   +5 more
doaj   +1 more source

Medication Related Osteonecrosis of the Jaw: Knowledge, Attitudes and Practice Patterns Among Australian Dental Practitioners

Australian Dental Journal, EarlyView.
ABSTRACT Background Medication related osteonecrosis of the jaw (MRONJ) is a debilitating condition associated with antiresorptive and antiangiogenic therapies. As the use of these medications continues to increase, dental practitioners play a critical role in prevention and management of at‐risk patients. This survey evaluated the awareness, knowledge
Ying Shi Chang, Christopher Friel, Gary Low, Albert Yaacoub, Stephen Clive Cox   +4 more
wiley   +1 more source

Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review

, 2023
Abduelmula R Abduelkarem,1,2 Adnane Guella,3 Amar M Hamrouni,4 Mohammed M Hassanein,1 Ahmed Nasr,5 Owais Rana6 1Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates; 2Research
Hassanein MM, Guella A, Hamrouni AM, Nasr A, Rana O, Abduelkarem AR   +5 more
core  

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source

Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic mice

Frontiers in Endocrinology
BackgroundReceptor activator of nuclear factor-κB ligand (RANKL) plays a central role in regulating osteoclast formation and bone resorption, while its inhibition by the monoclonal antibody denosumab serves as an effective antiresorptive treatment for ...
Vagelis Rinotas, Eleftheria-Dimitra Ntouskou, Melina Dragolia, Vasileios Ntafis, Maria P. Yavropoulou, Athanasios D. Anastasilakis, Polyzois Makras, Eleni Douni, Eleni Douni   +8 more
doaj   +1 more source

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

BMC Cancer, 2019
Background While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF).
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi, Toshimi Takano   +15 more
doaj   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy

Orthopaedic Surgery, 2023
Objective The osteoclastic bone resorption inhibitors might have positive effect in preventing femoral head collapse in patients with osteonecrosis of the femoral head (ONFH).
Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han   +7 more
doaj   +1 more source

Bone Health and Aging in Klinefelter Syndrome

Andrology, EarlyView.
ABSTRACT Klinefelter syndrome (KS) is typically diagnosed in young adults, but advances in prenatal testing have led to its recognition at a much earlier age. Conversely, diagnosis in late adulthood remains uncommon, but still occurs. Independently from the age at diagnosis, KS individuals now receive more accurate and tailored care management than in ...
Filippo Vignali, Daniele Renda Livraghi, Francesco Costantino, Sara De Vincentis, Vincenzo Rochira   +4 more
wiley   +1 more source

Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study

, 2021
Objective:Denosumab is a humanized monoclonal antibody that targets the receptor activator of nuclear factor kappa-beta ligand. This study aimed to evaluate the effectiveness of denosumab, a new-generation drug, in treating postmenopausal osteoporosis ...
Nihal Tezel, Öznur Ecerkale, Damla Cankurtaran, Ece Ünlü Akyüz   +3 more
core   +1 more source